James Black: Difference between revisions
CSV import |
CSV import |
||
| Line 35: | Line 35: | ||
[[Category:Academics of King's College London]] | [[Category:Academics of King's College London]] | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 15:32, 17 March 2025
James Black[edit]
Sir James Whyte Black (14 June 1924 – 22 March 2010) was a Scottish pharmacologist who was awarded the Nobel Prize in Physiology or Medicine in 1988 for his work in drug development. He is best known for his pioneering work in the development of beta-blockers and H2 receptor antagonists, which have had a profound impact on the treatment of cardiovascular diseases and peptic ulcers, respectively.
Early Life and Education[edit]
James Black was born in Uddingston, Lanarkshire, Scotland. He attended Beath High School in Cowdenbeath and later studied medicine at the University of St Andrews, where he graduated in 1946. After completing his medical degree, Black worked as a lecturer in physiology at the University of St Andrews.
Career and Research[edit]
Black's career in pharmacology began when he joined the Imperial Chemical Industries (ICI) Pharmaceuticals division in 1958. It was here that he developed propranolol, the first successful beta-blocker, which revolutionized the treatment of angina and hypertension. Beta-blockers work by blocking the effects of adrenaline on the heart, thus reducing heart rate and blood pressure.
In 1964, Black moved to Smith, Kline & French (now part of GlaxoSmithKline), where he developed cimetidine, the first H2 receptor antagonist. Cimetidine was a breakthrough in the treatment of peptic ulcers, as it effectively reduced stomach acid production by blocking histamine receptors in the stomach lining.
Nobel Prize and Later Work[edit]
In 1988, James Black was awarded the Nobel Prize in Physiology or Medicine, shared with Gertrude B. Elion and George H. Hitchings, for their discoveries of important principles for drug treatment. Black's work laid the foundation for the development of many other drugs and therapeutic agents.
After his time in the pharmaceutical industry, Black returned to academia, holding positions at University College London, the University of Glasgow, and King's College London. He continued to contribute to the field of pharmacology until his retirement.
Legacy[edit]
James Black's contributions to medicine have saved countless lives and improved the quality of life for millions of patients worldwide. His work exemplifies the impact of pharmacological research on clinical practice and patient care.
Also see[edit]
- Beta-blocker
- H2 receptor antagonist
- Nobel Prize in Physiology or Medicine
- Pharmacology
- Drug development
Template:Nobel Prize in Physiology or Medicine Laureates 1981-2000